Skip to content

Released Mar 21, 2019, after the close

10-K filed Mar 22, 2019, 81 days after period end · 0001390478-19-000017

Q4 2018 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$13.32MderivedN/M vs Q4 2017N/M vs Q3 2018
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Cash Flowderived-$4,555,000N/M

What the release said

The release

Same quarter

MetricQ4 2018derived from reported figuresQ4 2017derived from reported figuresQ4 2016derived from reported figuresQ4 2015derived from reported figures
Net Income-$13.32M-$8.79M$352.00K-$19.68M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR